Andrea Lobo,  —

Tenax Therapeutics is planning to start a Phase 3 clinical trial of TNX-103 — oral levosimendan — to treat pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) later this year. People with PH-HFpEF have a normal heartbeat, but the heart muscle is too stiff to fill…

A long noncoding RNA molecule (lncRNA) — a long segment of RNA that regulates protein production in the body — may activate or inhibit genes associated with pulmonary arterial hypertension (PAH), according to researchers in China. In their study, a lncRNA was found at higher levels in children with…

Referral to a specialized chronic thromboembolic pulmonary hypertension (CTEPH) center for follow-up treatment after a pulmonary embolism (PE) — a blood clot that blocks an artery in the lungs — is more likely if patients live closer to the center and have access to a primary healthcare provider, a…

The development program of AER-901, Aerami Therapeutics’ inhaled formulation of imatinib, will include pulmonary hypertension associated with interstitial lung disease (PH-ILD). According to the company, data from a completed Phase 1 clinical trial support the progression of AER-901 into Phase 2 trials for pulmonary arterial hypertension (PAH)…

A peptide called apelin-17 may be used as a diagnostic biomarker for idiopathic pulmonary arterial hypertension (IPAH), according to the results of a new study. Apelin-17 levels were found to detect IPAH with an accuracy similar to NT-proBNP and GDF-15 — two established biomarkers for pulmonary hypertension (PH)…

Treatment with swietenine — extracted from the seeds of Swietenia macrophylla, a tree commonly called mahogany — eased the remodeling of lung blood vessels in a mouse model of pulmonary hypertension (PH). Researchers in China found that swietenine worked against this disease hallmark by inhibiting the growth of smooth muscle cells…

Pulmonary arterial hypertension (PAH) is associated with high utilization of healthcare resources by patients and with productivity loss, starting years before diagnosis, according to a study in Sweden. “The economic and clinical burden associated with PAH suggests that strategies for earlier diagnosis and more effective treatments are warranted,” researchers…

Liquidia and Sandoz will collaborate with Mainbridge Health Partners to develop a new subcutaneous or under-the-skin infusion pump for treprostinil — a generic form of Remodulin — for treating people with pulmonary arterial hypertension (PAH). The exclusive rights to promote and market treprostinil injection belong…

Despite treatment advances in pulmonary hypertension (PH) over the last two decades, the age-adjusted PH-related death rate in the U.S. increased annually between 1999 and 2019, with mortality climbing by nearly 2% each year, a new study found. The simultaneous presence of PH and disease of the left side…